Peptide library

A small-molecule NNMT inhibitor (technically not a peptide) studied in animal models for body-composition and aging endpoints. No human trials published. Often grouped with research peptides because of the community context.

A pro-apoptotic peptidomimetic targeting white-adipose vasculature, studied in obese non-human primates with significant weight loss. Human trials have not been completed; renal toxicity is a known concern. Use is highly experimental.

A 16-amino-acid fragment of human growth hormone designed to retain lipolytic activity without GH's mitogenic effects. Failed phase 3 obesity trials in humans. Continues to be researched and used off-label.

A long-acting amylin analog from Novo Nordisk in late-stage development, typically combined with semaglutide as CagriSema. Phase 2 data shows additive weight loss beyond semaglutide alone. Not yet approved.

A neuropeptide preparation derived from porcine brain, registered in many EU and Asian countries for stroke recovery and dementia. Multiple clinical trials with mixed but generally positive cognitive outcomes. Not approved in the US.

A short-acting modified GHRH(1-29) analog without the albumin-binding DAC linker. Produces brief, pulsatile GH release that more closely mimics natural physiology. Often paired with a GHRP for synergistic release.

A long-acting GHRH analog that binds serum albumin via a DAC linker, extending half-life to roughly a week. Limited human pharmacokinetic studies show sustained elevation of growth hormone and IGF-1. Most adoption is community-driven rather than clinical.

An oral hepatocyte-growth-factor mimetic developed at Washington State University. Preclinical studies report potent dendritic spine growth and cognitive improvement in rodent models. No human trials; dosing in community use is largely speculative.

A nine-amino-acid peptide first isolated from rabbit cerebral venous blood during sleep. Human studies on sleep efficacy are mixed and dated. Some research interest persists for chronic pain and stress.

A four-amino-acid peptide derived from the pineal hormone epithalamin. Primarily studied in Russian gerontology research with claims around telomerase activity and circadian regulation. Western peer-reviewed evidence is sparse; treat all longevity claims as preliminary.

A small NCAM-derived peptide investigated as a cognition enhancer in animal models. Some early human safety work in Denmark; efficacy data in humans is limited. Community use is rare.

A senolytic peptide that selectively triggers apoptosis in senescent cells, originally reported in a 2017 Cell paper. Restored fitness and fur density in aged mice. No human trials; do not extrapolate animal results.

A naturally occurring copper-binding tripeptide whose serum levels decline with age. Best studied in topical cosmetic and wound-healing contexts; injectable use is community-driven and not FDA-approved. Often researched for skin remodeling, hair growth, and connective-tissue support.

An endogenous tripeptide and the body's major intracellular antioxidant (not a research peptide in the strict sense). Oral bioavailability is poor; injectable and liposomal forms are common in community use. Human evidence on supplementation is mixed.

A six-amino-acid GHRP with one of the strongest GH-release responses among the GHRPs. Tachyphylaxis and cortisol/prolactin elevation limit long-term use. Human data exists from older trials.

A 24-amino-acid mitochondrial-derived peptide first identified as protective in Alzheimer's models. Plasma levels decline with age. Preclinical only — no human therapeutic trials of synthetic humanin to date.

A modified IGF-1 with extended half-life from reduced binding-protein affinity. Used in research as a long-acting IGF-1 analog; not approved for human use. Community interest is in muscle hypertrophy and recovery, with significant hypoglycemia risk.

A selective ghrelin/GHS-R agonist that triggers GH release with minimal effect on cortisol or prolactin. One of the most-studied GH secretagogues in early human trials, though long-term data is limited. Commonly stacked with a GHRH analog for additive release.

The C-terminal tripeptide of alpha-melanocyte stimulating hormone with anti-inflammatory activity in animal models of colitis and skin inflammation. No formal human trials; community interest centers on gut health.

An eight-amino-acid tight-junction regulator investigated for celiac disease as adjunct to a gluten-free diet. Reached phase 3 (CeDLara) but did not meet primary endpoint. Community interest is in 'leaky gut' contexts.

Another Khavinson short-peptide bioregulator, reported to support thymus-related immune function in aged animals. Human evidence is limited to small Russian studies. Community use is niche.

The only human cathelicidin antimicrobial peptide. Shows broad antimicrobial activity and immunomodulatory effects in vitro. Therapeutic use is investigational; safety in humans is not well established at supplemental doses.

A non-selective melanocortin receptor agonist originally developed at Arizona State for tanning. Not FDA-approved and frequently warned against by health authorities due to side-effect profile (nausea, blood-pressure changes, mole darkening). Community use exists despite the risks.

An orally bioavailable, non-peptidic ghrelin receptor agonist. Human studies including a 2-year trial in older adults show sustained increases in GH and IGF-1, with appetite increase and water retention as common effects. Not FDA-approved.

A 16-amino-acid peptide encoded within mitochondrial DNA. Preclinical studies show effects on insulin sensitivity, exercise capacity, and metabolic homeostasis. Human evidence is minimal; community interest is in metabolic flexibility and aging.

An essential coenzyme (not technically a peptide) often grouped with peptide therapies in community contexts. Levels decline with age. Limited human studies on supplementation; precursor strategies (NR, NMN) have more direct clinical research.

FDA-approved as Elmiron (oral) for interstitial cystitis. Strictly speaking a semi-synthetic glycosaminoglycan rather than a peptide, but listed here for community context. Long-term use carries documented retinal-toxicity risk.

A short tripeptide bioregulator from Khavinson's Russian gerontology school. Animal data claims neuroprotective effects; Western peer-reviewed replication is sparse. Treat all longevity/cognitive claims as preliminary.

FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. A melanocortin receptor agonist that works centrally rather than vasodilation. Effective in randomized trials; off-label community use is broad.

An investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly. Phase 2 data showed up to 24% mean body-weight reduction at 12 mg over 48 weeks. Not yet FDA-approved; phase 3 trials ongoing.

A heptapeptide developed in Russia as an anxiolytic, used clinically there for generalized anxiety. Western peer-reviewed studies are limited and small. Often paired with semax for cognitive support.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), with an oral form (Rybelsus). Large randomized trials show 12–17% body-weight reduction at the 2.4 mg weekly dose. One of the strongest evidence bases of any peptide listed here.

A seven-amino-acid analog of ACTH(4-10) used in Russia for stroke recovery and cognitive disorders. Western evidence is limited to small studies. Community interest centers on focus and neuroprotection.

A GHRH(1-29) analog historically FDA-approved for pediatric growth hormone deficiency under the brand Geref; current US availability is via compounding pharmacies. Stimulates the pituitary's own GH production rather than supplying exogenous GH. Considered one of the better-studied peptides in this category.

A mitochondria-targeted tetrapeptide in clinical development for primary mitochondrial myopathy and Barth syndrome. Late-stage trials are mixed but the safety profile is established. Community interest is in age-related fatigue and recovery.

A synthetic version of the active region of thymosin β4, a naturally occurring repair peptide. Preclinical evidence supports roles in actin regulation, angiogenesis, and wound healing. Human research is sparse; community use centers on tendon and ligament recovery.

FDA-approved (Egrifta) for the reduction of visceral adipose tissue in HIV-associated lipodystrophy. A stabilized GHRH analog with a longer half-life than sermorelin. Off-label community interest centers on visceral fat reduction.

An immunomodulatory peptide approved in over 30 countries (not the US) under the name Zadaxin for chronic hepatitis B and as an immune adjuvant. Decent evidence base in oncology and infection-recovery contexts. The most clinically established immune-focused peptide listed here.

FDA-approved (Mounjaro for type 2 diabetes, Zepbound for chronic weight management). A dual GIP/GLP-1 agonist with the largest weight-loss effect of any approved pharmaceutical, averaging 21% reduction at 15 mg weekly in SURMOUNT-1. Strong evidence base.

A 15-amino-acid synthetic fragment derived from a gastric protein. Most evidence is from animal models showing accelerated soft tissue, tendon, and gut repair. Human data is limited; the peptide is not FDA-approved for any indication. Often researched by users seeking faster recovery from soft-tissue injuries.